Published Peer Reviewed Journal Articles

Publications can be viewed at: ResearchGate, Google Scholar, Scopus (Author ID: 56835162600), ResearcherID (ID: U-3708-2018) or Orcid (ID: 0000-0003-0699-2250)
  1. Bartlett SR, Verich A, Finlayson R, Baker D, Bloch M, Doyle J, Shaw D, Hajkowicz K, Read P, Hellard M, Filep E, Yee J, Martinez M, Lamoury FMJ, Lin L, Dore GJ, Matthews GV, Applegate T, Martinello M. Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct acting antiviral era: a molecular epidemiology study among participants in the CEASE cohort. Accepted in Health Science Reports, June 2022.
  2. Bartlett S, Tiwana A, Dhillon D. ‘Sexually Transmitted and Blood-Borne Infection testing and linkage to care during incarceration: there’s no time like the prison time!’ Accepted in University of British Columbia Medical Journal, April 2022.
  3. Makuza JD, Jeong D, Soe, P, Bartlett S, Velásquez García H, Binka M, Adu P, Dushimiyimana D, Dushimiyimana V, Maliza C, Nisingizwe M, Rwibasira G, Tuyishime A, Janjua N. Impact of COVID-19 pandemic on HCV Care cascade in Rwanda: Ecological study from July 2019 to June 2021. Accepted in Clinical Liver Disease April 2022
  4. Yazdani K, Dolguikh K, Zhang W, Shayeginik S, Ly J, Cooper S, Trigg J, Bartlett S, Barrios R, Montaner J, Salters K. Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy. Accepted in PLOS ONE March 2022
  5. Nikiforuk AM, McMillan B, Bartlett SR, Márquez AC, Pidduck T, Kustra J, Goldfarb DM, Barakauskas V, Sinclair G, Patrick DM, Sadarangani M, Ogilvie GS, Morshed M, Sekirov I, Jassem AN. Performance of Immunoglobulin G Serology on Finger Prick Capillary Dried Blood Spot Samples to Measure SARS-CoV-2 Humoral Immunogenicity. Accepted in Microbiology Spectrum, February 2022
  6. Cholette F, Mesa C, Harris A, Ellis H, Cachero K, Lacap P, Galipeau Y, Langlois MA, Gingras AC, Yansouni CP, Papenburg J, Cheng MP, Chakraborty P, Stein DR, Van Caeseele P, Bartlett S, Krajden M, Goldfarb D, McGeer A, Osiowy C, Hankins C, Mazer B, Drebot M, Kim J, on behalf of the Canadian Immunity Task Force (CITF) working group. Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison. PLOS ONE 16(12): e0261003. DOI: 10.1371/journal.pone.0261003  
  7. Wilton J, Wong S, Purssell R, Abdia Y, Chong M, Karim ME, MacInnes A, Bartlett SR, Balshaw RF, Gomes T, Yu A, Alvarez M, Dart RC, Krajden M, Buxton JA, Janjua NZ. Association between prescription opioid therapy for non-cancer pain and hepatitis C virus seroconversion: A retrospective administrative study. JAMA Netw Open. 2022;5(1): e2143050. DOI: 10.1001/jamanetworkopen.2021.43050
  8. Harland K, Richards H, Bonn M, Materniak S, Bartlett S. The need for evidence-based harm reduction services in correctional facilities during the COVID-19 pandemic. Accepted in Journal of Prisoners on Prisons, December 2021
  9. Binka M, Bartlett S, Velasquez H, Darvishian M, Jeong D, Prince A, Alvarez M, Wong S, Yu A, Samji H, Krajden M, Wong J, Janjua NZ. Impact of COVID-19-related public health measures on HCV testing in British Columbia, Canada: an interrupted time series analysis. Liver International, 2021. DOI: 10.1111/liv.15074
  10. Pearce M, Yu A, Bartlett S, Reitz C, Currie E, Westerby J, Jefferies H, Madsen J, Lamb J, Wilton J, Adu P, Clementi E, Wong S, Samji H, Alvarez M, Wong J, Krajden M, Janjua Z. Women in the 2019 hepatitis C cascade of care: Findings from the British Columbia Hepatitis Testers Cohort Study. BMC Women’s Health, 2021. DOI: 10.1186/s12905-021-01470-7
  11. Harney BL, Korchinski M, Young P, Scow M, Jack K, Linsley P, Bodkin C, Brothers TD, Curtis M, Higgs P, Mead TS, Hart A, Kilroy D, Bonn M, Bartlett SR. It is time for us all to embrace person-centred language for people in prison and people who were formerly in prison. International Journal of Drug Policy, 2021. DOI: 10.1016/j.drugpo.2021.103455
  12. Bartlett SR, Yu A, Wong S, Pearce M, Alvarez M, Samji H, Binka M, Buxton J, Butt ZA, Wong J, Gilbert M, Krajden M, Janjua NZ. The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from in the DAA era: A population-based study. Clinical Infectious Diseases, 2021 DOI: 10.1093/cid/ciab546
  13. Jeong D, Karim E, Wong S, Wilton J, Butt Z, Binka M, Adu P, Bartlett S, Pearce M, Clementi E, Yu A, Alvarez M, Samji H, Velasquez H, Abdia Y, Krajden M, Janjua N. Impact of HCV infection and ethnicity on incident type 2 diabetes: findings from a large population-based cohort in British Columbia. Accepted in BMJ Open Diabetes Research & Car, May 2021. DOI: 10.1136/bmjdrc-2021-002145
  14. Janjua NZ, Wong S, Abdia Y, Jeong D, Buller-Taylor T, Adu P, Samji H, Wilton J, Pearce M, Butt ZA, Yu A, Binka M, Bartlett S, Alvarez M, Krajden M. The impact of direct acting antiviral therapies for treatment of HCV on mortality in a large population-based cohort study, Accepted in Journal of Hepatology March 2021 DOI: 10.1016/j.jhep.2021.05.028
  15. Bartlett SR, Buxton J, Palayew A, Picchio CA, Janjua NZ, Kronfli N., Hepatitis C Virus Prevalence, Screening, and Treatment Among People Who Are Incarcerated in Canada: Leaving No One Behind in the Direct-Acting Antiviral Era. Clinical Liver Disease, 2021;17(2): 75-80. DOI: 10.1002/cld.1023
  16. Bonn M, Palayew A, Bartlett S, Brothers TD, Touesnard N, Tyndall M, “The Times They Are a-Changin’”: Addressing Common Misconceptions About the Role of Safe Supply in North America’s Overdose Crisis. Journal of Studies on Alcohol and Drugs, 2021;82(1): 158-160. DOI: 10.15288/jsad.2021.82.158
  17. Kronfli N, Dussault C, Bartlett SR, Fuchs D, Kaita K, Jennings L, Barrett L and Cox J. Disparities in hepatitis C care across Canadian provincial prisons: Implications for hepatitis C micro-elimination. Canadian Liver Journal, 2021, e20200035. DOI: 10.3138/canlivj-2020-0035
  18. Adu P, Rossi C, Wong S, Binka M, Wilton J, Wong J, Butt ZA, Bartlett SR, Jeong D, Pearce M, Darvishian M, Yu A, Alvarez M, Velásquez García H, Krajden M, Janjua NZ. HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men. Liver International, 2021;41(3);482-493 DOI: 10.1111/liv.14762
  19. Pearce M, Yu A, Alvarez M, Bartlett SR, Binka M, Jeong D, Clementi E, Adu P, Wilton J, Yoshida E, Pick N, Buxton J, Wong J, Jassem A, Krajden M, Janjua NZ. Prenatal Hepatitis C Screening, Diagnoses, and Follow-Up testing in British Columbia, 2008-2019’. PLOS ONE, 2020;15(12), e0244575. DOI: 10.1371/journal.pone.0244575
  20. Samji H, Yu A, Wong, S,  Wilton J,  Binka M, Alvarez M, Bartlett S, Pearce M, Adu P, Jeong D, Clementi E, Buxton J, Gilbert M, Krajden M, Janjua N. Drug-related deaths in a population-level cohort of people living with and without hepatitis C virus in British Columbia, Canada. International Journal of Drug Policy, 2020:86 e102989 DOI: 10.1016/j.drugpo.2020.102989
  21. Bonn M, Palayew A, Bartlett S, Brothers TD, Touesnard N, Tyndall M, Addressing the Syndemic of HIV, Hepatitis C, Overdose, and COVID-19 Among People Who Use Drugs: The Potential Roles for Decriminalization and Safe Supply: Journal of Studies on Alcohol and Drugs, 2020;81(5): 556-560. DOI: 10.15288/jsad.2020.81.556
  22. Clementi E., Bartlett S., Wong S., Yu A., Pearce M., Binka M., Alvarez M., Jeong D., Wilton J., Adu P., Abdia Y., McKee G., Wong J., Butt Z., Krajden M., Otterstatter M., Buxton J., Janjua N., Syndemic profiles of people living with hepatitis C virus using population-level latent class analysis to optimize health services. International Journal of Infectious Diseases, 2020; 100: 27-33. DOI: 10.1016/j.ijid.2020.08.035
  23. Wilton J, Wong S, Yu A, Cook D, Alvarez M, Binka M, Darvishian M, Yoshida E, Ramji A, Krajden M, Bartlett S, Pearce M, Adu P, Jeong D, Butt ZA, Janjua NZ. Real-world effectiveness of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection: A population-based cohort study. Open Forum Infectious Diseases, 2020; 7(3), ofaa055. DOI: 10.1093/ofid/ofaa055
  24. Bartlett SR, Yu A, Chapinal N, Rossi C, Butt ZA, Wong S, Darvishian M, Gilbert M, Wong J, Binka M, Alvarez M, Tyndall M, Krajden M, Janjua NZ. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of Direct Acting Antivirals, 2019: Liver International, DOI: 10.1111/liv.14227
  25. Martinello M, Yee J, Bartlett SR, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle J, Shaw D, Hellard M, Petoumenos K, Lin L, Marks P, Applegate T, Dore GJ, Matthews GV. CEASE study team, Moving towards hepatitis C micro-elimination among people living with HIV in Australia: the CEASE study, 2019: Clinical Infectious Diseases, ciz985, DOI: 10.1093/cid/ciz985
  26. Rossi C, Jeong D, Wong S, McKee G, Butt ZA, Buxton J, Wong J, Darvishian M, Bartlett S, Samji H, Yu A, Binka M, ALvarez M, Adu PA, Tyndall M, Krajden M, Janjua NZ, Sustained Virologic Response from Interferon-based Hepatitis C regimes IS associated with Reduced risk of Extrahepatic Manifestations, 2019: Journal of Hepatology, DOI: 10.1016/j.jhep.2019.07.021
  27. Darvishian M, Wong S, Binka M, Yu A, Ramji A, Yoshida E, Wong J, Rossi C, Butt Z, Bartlett S, Pearce M, Samji H, Cook D, Alvarez M, Chong M, Tyndall M, Krajden M, Janjua N. Loss to follow-up: a significant barrier in the treatment cascade with direct-acting therapies, 2019. Journal of Viral Hepatitis, DOI: 10.1111/jvh.13228
  28. Bartlett SR, Krajden M, Janjua N, Buller-Taylor T. Using population-level integrated health data to monitor and assess patients’ progression across care and treatment continuums. British Columbia Medical Journal, 2019; 61(2):78-80. https://bcmj.org/Vol.61/No.2/pages.78,80
  29. Bartlett SR, Applegate T, Jacka B, Lamoury F, Bull R, Danta M, Bradshaw D, Lloyd AR, Hellard M, Dore GJ, Matthews GV, Grebely J. A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004-2015. Journal of the International AIDS Society, 2019; 22(2): e25222 DOI:10.1002/jia2.25222
  30. Bartlett SR, Fox P, Cabatingan H, Jaros A, Gorton C, Lewis R, Priscott E, Dore GJ, Russell DB. Demonstration of near-elimination of hepatitis C virus among a prison population: the Lotus Glen Correctional Centre hepatitis C treatment project. Clinical Infectious Diseases, 2018; 67(3): 460-463: DOI: 10.1093/cid/ciy210
  31. Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe A, Miller V, Ceccherini-Silberstein F, Bull RA, Douglas MW, Dore GJ, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL. Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance. Hepatology Communications, 2017, DOI: 10.1002/hep4.1050.
  32. Bartlett SR, Wertheim JO, Bull RA, Matthews GV, Lamoury FMJ, Scheffler K, Hellard M, Maher L, Dore GJ, Lloyd AR, Applegate TL, Grebely J. A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies. Journal of Viral Hepatitis, 2016; DOI: 10.1111/jvh.12652.
  33. Bartlett SR, Jacka B, Bull RA, Luciani F, Matthews GV, Lamoury FMJ, Hellard ME, Hajarizadeh B, Teutsch S, White B, Maher L, Dore GD, Lloyd A, Grebely J, Applegate TL. HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection. Infection, Genetics and Evolution, 2016; 37:252-258. DOI: 10.1016/j.meegid.2015.11.028
  34. Lamoury FMJ, Jacka B, Bartlett S, Bull R, Wong A, Amin J, Schinkel J, Poon AF, Matthews GV, Grebely J, Dore GJ, Applegate TL. The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis. PLOSone 2015; 10:1371. DOI: 10.1371/journal.pone.0131437
  35. Lamoury FMJ, Bartlett S, Jacka B,  Hajarizadeh B, Grebely J, Matthews GV, Dore GJ, Applegate TL. Interferon Lambda 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types. The Journal of Molecular Diagnostics 2015; 17(5): 583–589. DOI: 10.1016/j.jmoldx.2015.05.003
  36. Bartlett S, Seeliger J, Burnell JN. Identification of critical residues in the bifunctional phosphoenolpyruvate synthetase kinase/phosphotransferase of Escherichia coli. Current Topics in Biochemical Research 2012; 14(1):77-83. ISSN: 0972-4583​
I acknowledge that I am an uninvited white settler living on the Traditional, Unceded, Ancestral, & Continually Occupied territories of the xʷməθkwəy̓əm (Musqueam), Skwxwú7mesh (Squamish), and sel̓íl̓witulh (Tsleil-waututh) Nations. I am grateful to the First Peoples of Turtle Island for their continued care and stewardship of these lands since time immemorial.